Stockholders' Equity (Deficiency) (Details) - USD ($) |
1 Months Ended | 12 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|---|
Dec. 03, 2020 |
Nov. 25, 2020 |
Nov. 06, 2020 |
Mar. 10, 2020 |
Dec. 31, 2020 |
Dec. 31, 2020 |
Dec. 31, 2019 |
Nov. 05, 2020 |
Dec. 31, 2018 |
|
| Stockholders' Equity (Deficiency) (Details) [Line Items] | |||||||||
| Share, Issued (in Shares) | 150,000 | 150,000 | |||||||
| Share, outstanding (in Shares) | 1,763,652 | ||||||||
| Stated balance of series A preferred stock assumed in connection with the business combination | $ 3,333,333 | ||||||||
| stated value | 333,333 | ||||||||
| Cash issuance cost | 318,333 | ||||||||
| Warrant issuance costs | 103,402 | ||||||||
| Fair value of bifurcated redemption feature | $ 218,000 | 1,167,000 | |||||||
| Issuance reduced conversion price description | On November 25, 2020, a dilutive issuance reduced the conversion price to the lower of (a) 96% of the lowest volume-weighted-average-price of the common stock during the five-day period preceding the conversion date; or (b) $5.28, both subject to a floor of $2.00 per share. | ||||||||
| Fair value of derivative liabilities | $ 606,000 | ||||||||
| Carrying value of the preferred stock | 1,411,265 | ||||||||
| Derivative Liabilities | 1,773,000 | ||||||||
| Fair value of the preferred stock | 3,531,924 | ||||||||
| Deemed dividend income | $ 565,659 | ||||||||
| Stockholders’ Equity , Description | During the period from November 30, 2020 to December 18, 2020, the 1,000,000 shares of Series A Preferred of the Company with a total conversion value of $3,666,667 were converted into shares of the Company’s common stock at conversion prices of between $2.00 and $2.31 per share, pursuant to the terms of such preferred stock. The bifurcated redemption features were marked-to-market just prior to each conversion, resulting in an aggregate charge of $42,068 to change in fair value of derivative liabilities and the $260,068 fair value of the bifurcated redemption features were derecognized on the conversion dates. At conversion, the aggregate $3,531,924 carrying value of the preferred stock and the $260,068 fair value of the derivative liability were derecognized and we recognized the $4,349,035 fair value of the 1,614,144 shares of common stock issued. The difference of $557,043 was recorded as deemed dividend expense, including $333,333 associated with the make-whole premiums and $223,710 associated with the contingent beneficial conversion feature. Due to such conversions, the Company currently has no shares of Series A Preferred issued or outstanding. | ||||||||
| Dividend | $ 333,333 | ||||||||
| Beneficial Conversion Feature (in Shares) | 223,710 | ||||||||
| Extinguishment on gain | $ 565,659 | ||||||||
| Special Voting Shares (in Shares) | 2,990,904 | ||||||||
| Common stock shares authorized (in Shares) | 100,000,000 | 100,000,000 | 100,000,000 | ||||||
| Common stock par value (in Dollars per share) | $ 0.0001 | $ 0.0001 | $ 0.0001 | ||||||
| Shares of common stock issued (in Shares) | 12,800,454 | ||||||||
| Shares of common stock issued for cash consideration (in Shares) | 64,657 | ||||||||
| Services valued | $ 1,130,656 | ||||||||
| Services valued | 333,145 | ||||||||
| Fair value | 12,992,470 | ||||||||
| Fair value of common stock issued | 45,866,502 | ||||||||
| Common stock issued for cash | $ 12,292 | $ 2,617 | $ 2,617 | 1,384 | |||||
| Cash proceeds for issuance of common stock | $ 72,500 | ||||||||
| Stock based compensation issued common stock (in Shares) | 240,540 | ||||||||
| Grant date value of common stock issued | $ 1,057,989 | ||||||||
| Shares issued upon conversion of convertible debt (in Shares) | 2,102,038 | ||||||||
| Fair value of common stock issued upon conversion of convertible debt | $ 6,466,353 | ||||||||
| Shares issued (in Shares) | 1,619,144 | ||||||||
| Shares of common stock issued upon conversion of common stock equivalents (in Shares) | 1,521,157 | ||||||||
| Options exercisable (in Dollars per share) | $ 2.49 | $ 11.50 | $ 11.50 | ||||||
| Grant date value | $ 93,575 | ||||||||
| Unrecognized stock-based compensation expense | $ 85,777 | ||||||||
| Weighted average remaining vesting period | 328 days | ||||||||
| Stock-based compensation recorded | $ 7,798 | ||||||||
| Reserved common stock (in Shares) | 3,718,140 | ||||||||
| Contingently Redeemable Shares , Description | On July 16, 2019, in connection with the Reorganization, the Company issued 2,694,053 shares to a consultant that were subject to redemption by 180 for an aggregate redemption price of $4.00 if (i) the closing of the Business Combination did not occur on or prior to October 31, 2019; or (ii) the consultant terminated his service with 180 prior to October 31, 2019. | ||||||||
| Modification of stock award - related party | $ 0 | $ 12,959,360 | |||||||
| CBR Pharma [Member] | |||||||||
| Stockholders' Equity (Deficiency) (Details) [Line Items] | |||||||||
| Share, Issued (in Shares) | 1,664,072 | 1,664,072 | |||||||
| KBL [Member] | |||||||||
| Stockholders' Equity (Deficiency) (Details) [Line Items] | |||||||||
| Common stock shares issued (in Shares) | 1,519,628 | ||||||||
| Board of Directors [Member] | |||||||||
| Stockholders' Equity (Deficiency) (Details) [Line Items] | |||||||||
| Shares issued (in Shares) | 50,000 | ||||||||
| Common Stock [Member] | |||||||||
| Stockholders' Equity (Deficiency) (Details) [Line Items] | |||||||||
| Share, Issued (in Shares) | 2,854,012 | ||||||||
| Share, outstanding (in Shares) | 26,171,225 | 26,171,225 | 13,846,925 | 1,046,471 | |||||
| Fair value | $ 285 | ||||||||
| Shares aggregate (in Shares) | 9,881,785 | ||||||||
| Common stock shares issued (in Shares) | 482,894 | ||||||||
| Shares issued (in Shares) | 1,619,144 | ||||||||
| Series A Preferred Stock [Member] | |||||||||
| Stockholders' Equity (Deficiency) (Details) [Line Items] | |||||||||
| Preferred stock shares authorized (in Shares) | 5,000,000 | ||||||||
| preferred stock, par value (in Dollars per share) | $ 0.0001 | ||||||||
| Dividend | 10.00% | ||||||||
| Share, Issued (in Shares) | 1,000,000 | 1,000,000 | |||||||
| Share, outstanding (in Shares) | 1,411,265 | 1,411,265 | |||||||
| Carrying value of preferred stock | $ 1,922,068 | ||||||||
| Fair value of series A preferred stock | $ 4,349,035 | ||||||||
| Preferred Class A [Member] | |||||||||
| Stockholders' Equity (Deficiency) (Details) [Line Items] | |||||||||
| Preferred stock shares authorized (in Shares) | 1 | 1 | 1 | ||||||
| Preferred shares issued (in Shares) | 1,000,000 | 1 | 1 | 1 | |||||
| Common Class A [Member] | |||||||||
| Stockholders' Equity (Deficiency) (Details) [Line Items] | |||||||||
| Conversion price, per share (in Dollars per share) | $ 5.28 | ||||||||